Upon joining the study, you will attend an initial visit. During this visit, you will undergo a series of assessments to confirm your eligibility for the trial. This includes a review of your medical history and a physical examination.

You will be asked to provide informed consent, which means you agree to participate in the study after understanding all the details and potential risks involved.

After the initial assessments, you will be randomly assigned to one of two groups. One group will receive the active medication, povorcitinib, and the other group will receive a placebo, which looks like the medication but does not contain the active ingredient.

This process is double-blind, meaning neither you nor the study staff will know which group you are in, to ensure unbiased results.

If you are in the group receiving povorcitinib, you will take the medication orally in the form of a tablet. The dosage and frequency will be specified by the study team.

If you are in the placebo group, you will take the placebo tablet in the same manner as the active medication group.

Throughout the study, you will have regular follow-up visits. These visits are scheduled to monitor your health and the effects of the medication.

During these visits, you will undergo various assessments, including physical examinations and questionnaires about your symptoms and any side effects you may experience.

The treatment phase of the study will last for a specified duration, after which you will stop taking the study medication.

You will have a final visit to assess your condition and gather any remaining data needed for the study.

After completing the treatment phase, you may be asked to participate in follow-up visits to monitor your health over a longer period.

These visits help the study team understand the long-term effects of the medication.